Human IL-13 Variant
Slide this table
| Cat-Nr. | 100-343 |
| Size | 10 µg |
| Price | 199 € |
| Source | E. coli |
| Formulation | lyophilized |
| Purity Confirmation | > 98% by SDS-PAGE & HPLC analyses |
| Length [aa] | 114 |
| Molecular Weight | 12.3 kDa |
| Endotoxin Levels | < 0.1 ng/µg of protein (<1EU/µg) |
| Biological Activity | This IL-13 analog shows a two fold increase, relative to wild type IL-13, in bioactivity as measured by the in-vitro dose dependent activation of STAT6 and IL-13 dependent gene induction in transfected A201.1 cells. This analog has also been shown to exhibit increased in vivo activity compared to wild type IL-13, as measured by the induction of airway hyper-responsiveness. |
| Species Reactivity | Mouse, Human |
| Synonyms | IL13; ALRH; BHR1; P600; IL-13 |
| Description | IL-13 is an immunoregulatory cytokine produced primarily by activated Th2 cells, and also by mast cells and NK cells. Targeted deletion of IL-13 in mice resulted in impaired Th2 cell development and indicated an important role for IL-13 in the expulsion of gastrointestinal parasites. IL-13 exerts anti-inflammatory effects on monocytes and macrophages and it inhibits the expression of inflammatory cytokines such as IL-1β, TNF-α, IL-6 and IL-8. IL-13 has also been shown to enhance B cell proliferation and to induce isotype switching resulting in increased production of IgE. Blocking of IL-13 activity inhibits the pathophysiology of asthma. Human and murine IL-13 is cross-species reactive. A variant of IL-13 shows enhanced functional activity compared with the wild type IL-13. The genetic variant, termed human IL-13 analog, is a mature 114 amino acid protein with a substitution of Q for R at position 112. |
| Protein Sequence | MSPGPVPPST ALRELIEELV NITQNQKAPL CNGSMVWSIN LTAGMYCAAL ESLINVSGCS AIEKTQRMLS GFCPHKVSAG QFSSLHVRDT KIEVAQFVKD LLLHLKKLFR EGQFN |
| Uniprot ID | P35225 |
| Protein RefSeq | NP_002179.2 |
| mRNA RefSeq | NM_002188 |
All prices plus VAT + possible delivery charges